Merck & Co., Inc. (NYSE:MRK) [Trend Analysis] retains strong position in active trade, as shares scoring 0.80% to $61.72 in a active trade session, while looking at the shares volume, around 8.24 Million shares have changed hands in this session. Merck Inc. (MRK) along with Eisai Inc. (ESALY) reported new interim data investigating Merck’s anti-PD-1 therapy, Keytruda or pembrolizumab, in combination with Eisai’s microtubule dynamics inhibitor, Halaven or eribulin, in patients with metastatic triple-negative breast cancer (TNBC).
The single-arm, multi-center phase 1b/2 study is investigating the combination of Keytruda with Halaven Injection in 21-day cycles in 95 patients with metastatic TNBC who had previously been treated with up to two lines of chemotherapy.
The primary endpoint of the phase 1b portion of the study is to assess the safety and tolerability of the combination. For the phase 2 portion of the study, the primary endpoint is investigator-assessed ORR and secondary endpoints include progression-free survival, overall survival and duration of response as well as efficacy in a subset of patients with PD-L1-positive tumors. The firm has institutional ownership of 74.40%, while insider ownership included 0.04%. MRK attains analyst recommendation of 2.40 with week’s performance of 2.44%. Investors looking further ahead will note that the Price to next year’s EPS is 3.21%.
Shares of HudBay Minerals Inc. (NYSE:HBM) [Trend Analysis] swings enthusiastically in regular trading session, it a loss of -2.84% to close at $6.85. HudBay Minerals Inc. (NYSE:HBM) disclosed that it has completed its previously declared offering of US$1.0 billion aggregate principal amount of senior notes in two series: (i) a series of 7.250% senior notes due 2023 in an aggregate principal amount of US$400 million and (ii) a series of 7.625% senior notes due 2025 in an aggregate principal amount of US$600 million. The New Notes will be governed by an indenture, dated as of December 12, 2016, among the company, the subsidiaries of the company party thereto as guarantors and U.S. Bank National Association, as trustee.
Hudbay plans to use the net proceeds from the offering of the New Notes (i) to fund the company’s Tender Offer, (ii) to fund the redemption or satisfaction and discharge of any Existing Notes that still remain outstanding following consummation of the Tender Offer and (iii) for general corporate purposes. The stock is going forward its fifty-two week low with 339.10% and lagging behind from its 52-week high price with -6.80%. HBM last month stock price volatility remained 5.72%.